Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results Selected for an Oral Presentation at the 2022 AACR Annual Meeting March 11, 2022
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 Priorities March 11, 2022
Safety and target engagement of an oral small-molecule sequestrant in adolescents with autism spectrum disorder: an open-label phase 1b/2a trial February 14, 2022
